Investor Presentation

Ref: ISLL:CH:2026 Date: 17th August, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB SUBJECT: INVESTOR PRESENTATION ON UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026. Dear Sir / Ma'am, Pursuant to Regulation 30 and other applicable provisions, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached herewith detailed Investors Presentation on Un-audited Financial Results for the quarter ended June 30, 2026. Kindly take the above information on record. For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer INVESTOR PRESENTATION MANAGEMENT COMMENTARY “Q1FY27 has set a strong tone for the year, demonstrating clear momentum as we continue to build on our transformation from an API player into a focused FDF manufacturer. The Company delivered a strong quarter, with operating EBITDA improving 2.85x YoY to ₹33.32 crore and op. EBITDA margin expanding by 1,258 bps YoY to 17.91%, reflecting better efficiencies, an improved business mix and disciplined execution across the organization. Standalone Operating Income grew 21.16% YoY to ₹186.08 crore, while PAT (excluding exceptional items) stood at ₹24.68 crore, a 2.04x YoY jump, with PAT margin improving by 827 bps YoY to 13.26%. The quarter saw the commercialization of our Viatris (Ireland, Europe), Manx (UK) and Arrotex (Australia) CDMO Partnerships/Own-Brands, expected to contribute an incremental ₹200-220 crore of revenue in FY27, alongside two new product launches, Ibuprofen Sachet for Europe and Macrogol Sachet for the UK and Australia. Looking ahead, we are expanding our Domestic business supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM). Internationally, supported by deeper own-brand penetration in UAE and Central Asia, the now-commercialized Viatris partnership, and continued investment in compliant manufacturing infrastructure including the Samba EU-GMP upgrade, we expect FY27 revenue growth of more than 50%, with a medium-term revenue CAGR of 20-25% and EBITDA margin expansion of 600-800 bps.” N.R. Munjal Chairman and Whole Time Director EVOLUTION & TRANSFORMATION JOURNEY Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories Inspection Ltd. Divested API Unit Group Consolidation through merger Ind-Swift Laboratories Ltd. | Growth & Regulatory Milestones of Ind Swift Ltd 2006 2007-11 2012 2013-18 2019-22 GBU MHRA Health Day-1 Philipines, Dry Suspension Manufacturing Canada, Launch of Thailand, South & Shiftpack Plant ANVISA, Generic, Africa & FDA facility added Established Commissioning Atorvastatin Approval. & Health of Formulation Launched patented Canada Facility at Ivabradine approval Oxalate in Europe Jammu IND - SWIFT LABORATORIES LTD – “The Before State” DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers Leadership in macrolides & complex chemistry Regulatory approvals from USFDA, MHRA, PMDA, 26 70+ Largest drug ANVISA, TGA, SFDA, ROF, NCPHP, Health Canada, MoH manufacturer in Countries supplied Manufacturing Oman, CDSCO India, HLfGP-Germany, FDA India North India Blocks across regulated + Proven CRAMS capability with innovator pharmerging markets collaborations Core Business Capabilities • Complex chemistry API development & scale-up • Integrated CRAMS operations for innovator projects • Backward-integrated, cost-efficient manufacturing • Strong regulatory compliance track record TRANSACTION SUMMARY & FINANCIAL RESET Synthimed Labs Transaction Summary Strategic Rationale Debt Elimination: Proceeds used Transaction Value : Slump Sale : to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile to net ₹1,650 Cr debt-free Portfolio company of India Resurgence Fund (Bain Capital & Capital Reallocation: Resources Piramal) freed to invest in higher-margin formulation businesses 3 manufacturing sites with USFDA, Retained Stake PMDA, EDQM approvals Business Realignment: Strategic exit from capital-intensive API ISLL holds 7.80% equity in operations Currently valued at ₹8,000-9,000 Cr (USD 1 bn) Synthimed, continuing the stake in growing APIs. Value Creation: Framework created for sustainable growth. POST - TRANSFORMATION OVERVIEW Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 850+ 520+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Approvals Years of (Effective 31 March 2024, NCLT-approved). registrations globally Experience • Consolidation created a single, streamlined, formulation-focused listed entity. • Repositioned as a pure-play Finished Dosage Formulation (FDF) 2,100+ 1200+ 85+ company. Dossiers filed Team Size Countries • Net debt-free balance sheet enabling growth investments Presence • Facilities accredited by UK-MHRA, TGA, Health Canada, WHO-GMP, ROF Germany, SFDA-Saudi Arabia, NCPHP-Hungary, MOH-Oman etc. Post-Merger Business Structure (New Operating Model) Domestic Division International Division (GBU) • Ethical, Generics, P2P & others (Q-DEN / Nova.) • Presence across 85+ countries. • 260+ marketing teams covering 20,000 retailers & • Strong CMO relationships & regulated market 25,000+ doctors. penetration. • Network of 2,400 stockists and 8 C&F. • Extensive dossier pipeline supporting long-term growth. MANUFACTURING INFRASTRUCTURE Global Business Unit (GBU) Domestic Unit Derabassi, Punjab Samba, J&K • Strategic Status: 100% Export-Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Capabilities: Dedicated blocks for Oral Solid Dosages (Tablets, Capsules, Sachets). • Key Approvals: UK-MHRA, TGA, Health • Focus: Domestic formulations Canada, WHO-GMP, MoH (Ethical, Generics, P2P, & others.) • Capacity: High-volume output capable of • Scale: Spans 14,700 sq. meters. supporting >₹10 Billion+ Revenue reach. • Accreditations: WHO-GMP, ISO • Tablets: 9 Billion (9,000 Million) / Annum. 9001:2008 • Capsules: 120 Million / Annum. • Sachets: 90 Million / Annum. • Sticks: 184 Million / Annum. • Dry Powder in Bottles: 33 Million / Annum • Pellets: 6,000 Kg / Annum R&D CAPABILITES Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 60+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validation. Core Strengths & Competencies Key R&D Metrics (Post-Transformation) Strategic Achievements • Regulatory Compliance: Capability for CTD / • Global Scale-Up: Executed site- • Global Filings: 2100+ dossiers filed across 85+ eCTD dossier preparation targeting UK, EU, variation/technology transfer for ~100 countries. Australia, and Canada. products from Europe, Canada, and • Success Rate: 520+ Global Approvals received. • Tech Transfer: Integrated QMS framework Australia to the GBU facility. • Pipeline: Active formulation pipeline targeting high- ensuring seamless site-transfer from R&D to • Developed and patented Clarithromycin growth therapeutic areas including Cardiac, Anti- com [Showing first 8,000 characters — download PDF for full document]